➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: April 10, 2021

DrugPatentWatch Database Preview

Litigation Details for Shire LLC v. Sandoz Inc. (D. Colo. 2011)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Shire LLC v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Shire LLC v. Sandoz Inc. (D. Colo. 2011)

Date Filed Document No. Description Snippet Link To Document
2012-11-13 141 United States Patent Nos. 5,854,290 (“the ‘290 patent”), 6,287,599 (“the ‘599 patent”), and 6,811,…plaintiffs’ patents [#19]. Drs. Arnsten, Rakic and Hunt are the owners of the ‘290 patent, entitled… at a pH in excess of 5.5.” ‘599 Patent: Claims 1-30, ‘794 Patent: Claims 3-12 The parties…specification and the purpose of the patent. Table 2 of the ‘599 patent compares the controls against the…The term “about.” Patent ‘599: Claims 18-23 Several claims in the ‘599 patent state that a component External link to document
2013-04-18 155 States Patent Nos. 6,287,599 and 6,811,794 (the “Shire Patents”) and United States Patent No. 5,854,290…PERMANENT INJUNCTION This action for patent infringement having been brought by Plaintiffs …5,854,290 (“the ’290 Patent”); Sandoz and Plaintiffs have entered into a Settlement Agreement…Shire has granted Sandoz a license to the Shire Patents (the 2576078.1 Case 1:11-cv-01110-RBJ-KMT…IV certification” with respect to the Shire Patents and seeking FDA approval to sell, offer for sale External link to document
2011-08-22 49 Scheduling Order infringement of U.S. Patent Nos. 5,854,290 (“the ’290 patent”), 6,287,599 (“the ’599 patent”), and 6,811,794…U.S. Patent No. 5,854,290 issued on December 29, 1998. 10. U.S. Patent No. 6,287,599 issued…,794 (“the ’794 patent”) (collectively, the “patents-in-suit”) and Sandoz Inc.’s (“Sandoz”) counterclaims…Dissolution Profiles.” The ’599 patent issued on September 11, 2001. The ’794 patent issued on November 2,…: The three patents in suit, namely the ’290, ’599 and ’794 patents, have expiration dates External link to document
2011-11-28 84 Status Report 15 Patent Claim(s) Term 6,287,599 … of body weight 6,287,599 1-30 pharmaceutically active agent …dependent 6,811,794 3-12 guanfacine 6,287,599 18 said pharmaceutically active agent… of from about 0.1 wt. % to about 70 wt. % 6,287,599 19 said pharmaceutically active agent…amount of from about 1 wt. % to about 40 wt. % 6,287,599 20 said non-pH dependent sustained External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.